ISOTRETINOIN
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Accutane · DIN 00582344 · 10mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accutane · DIN 00582344
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Health Canada: Marketed since 2026-07-22 · brand ACCUTANE · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 10 MG · company Cheplapharm schweiz gmbh · schedule Prescription
Ministry pays: $0.9313 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5128 · Verify on the e-Formulary ↗ (DIN 00582344)
Source record
DIN 00582344: Accutane
Raw flags: sec3=Y
Item: 843600035; group id 864; item number 2086; lccId None; manufacturer id HLR
Source form: Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.9738; ministry $0.9313
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00582344
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5128
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Clarus · DIN 02257955 · $0.9313
Shortage status: resolved shortage (ended 2025-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00582344
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clarus · DIN 02257955 · 10mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clarus · DIN 02257955
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-07-19
Health Canada: Marketed since 2010-03-01 · brand CLARUS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Clarus: Formulary list price $0.9313/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9313 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74319 · Verify on the e-Formulary ↗ (DIN 02257955)
Source record
DIN 02257955: Clarus
Raw flags: sec3=Y
Item: 843600035; group id 864; item number 2086; lccId None; manufacturer id MYL
Source form: Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.9313; ministry $0.9313
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02257955
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74319
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Accutane · DIN 00582344 · $0.9313
Shortage status: resolved shortage (ended 2026-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02257955
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Epuris · DIN 02396971 · 10mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Epuris · DIN 02396971
Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 10 MG · company Cipher pharmaceuticals inc · schedule Prescription
Epuris: Formulary list price $1.5441/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5441 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88198 · Verify on the e-Formulary ↗ (DIN 02396971)
Source record
DIN 02396971: Epuris
Raw flags: sec3=Y
Item: 843600095; group id 864; item number 2087; lccId None; manufacturer id CIP
Source form: Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $1.5441; ministry $1.5441
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02396971
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88198
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02396971
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Epuris · DIN 02396998 · 20mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Epuris · DIN 02396998
Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 20 MG · company Cipher pharmaceuticals inc · schedule Prescription
Epuris: Formulary list price $2.1365/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.1365 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88199 · Verify on the e-Formulary ↗ (DIN 02396998)
Source record
DIN 02396998: Epuris
Raw flags: sec3=Y
Item: 843600096; group id 864; item number 2088; lccId None; manufacturer id CIP
Source form: Cap; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $2.1365; ministry $2.1365
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02396998
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88199
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02396998
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Epuris · DIN 02397005 · 30mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Epuris · DIN 02397005
Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 30 MG · company Cipher pharmaceuticals inc · schedule Prescription
Epuris: Formulary list price $2.6871/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.6871 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88200 · Verify on the e-Formulary ↗ (DIN 02397005)
Source record
DIN 02397005: Epuris
Raw flags: sec3=Y
Item: 843600097; group id 864; item number 2089; lccId None; manufacturer id CIP
Source form: Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $2.6871; ministry $2.6871
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397005
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88200
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397005
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Accutane · DIN 00582352 · 40mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accutane · DIN 00582352
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Health Canada: Marketed since 2025-09-05 · brand ACCUTANE · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 40 MG · company Cheplapharm schweiz gmbh · schedule Prescription
Ministry pays: $1.9003 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5129 · Verify on the e-Formulary ↗ (DIN 00582352)
Source record
DIN 00582352: Accutane
Raw flags: sec3=Y
Item: 843600034; group id 864; item number 2090; lccId None; manufacturer id HLR
Source form: Cap; strength: 40mg
Recorded listing: General benefit
Source prices (unrounded): $1.9870; ministry $1.9003
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00582352
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5129
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Clarus · DIN 02257963 · $1.9003
Shortage status: resolved shortage (ended 2025-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00582352
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clarus · DIN 02257963 · 40mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clarus · DIN 02257963
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-07-19
Health Canada: Marketed since 2010-03-01 · brand CLARUS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 40 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Clarus: Formulary list price $1.9003/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.9003 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74320 · Verify on the e-Formulary ↗ (DIN 02257963)
Source record
DIN 02257963: Clarus
Raw flags: sec3=Y
Item: 843600034; group id 864; item number 2090; lccId None; manufacturer id MYL
Source form: Cap; strength: 40mg
Recorded listing: General benefit
Source prices (unrounded): $1.9003; ministry $1.9003
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02257963
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74320
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Accutane · DIN 00582352 · $1.9003
Shortage status: resolved shortage (ended 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02257963
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Epuris · DIN 02397013 · 40mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Epuris · DIN 02397013
Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27
Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 40 MG · company Cipher pharmaceuticals inc · schedule Prescription
Epuris: Formulary list price $3.1503/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.1503 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88201 · Verify on the e-Formulary ↗ (DIN 02397013)
Source record
DIN 02397013: Epuris
Raw flags: sec3=Y
Item: 843600098; group id 864; item number 2091; lccId None; manufacturer id CIP
Source form: Cap; strength: 40mg
Recorded listing: General benefit
Source prices (unrounded): $3.1503; ministry $3.1503
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397013
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88201
Therapeutic Notes (formulary)
Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397013
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered
Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, FLUOROURACIL, ZINC SULFATE
Some products covered without a code (check the product listing): COLLAGENASE
84:36 Miscellaneous Skin and Mucous Membrane Agents
· 6 products · General benefit · strengths: 10mg, 25mg · Cap
· 1 products · General benefit · strengths: 15% · Top Gel
· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk
· 1 products · General benefit · strengths: 5% · Cr
· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup
· 4 products · Listed, not a benefit (2),
Limited Use, codes 442 (2) · strengths: 10mg, 30mg · Cap
· 1 products ·
Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr
· 1 products ·
Limited Use, codes 191 · strengths: 50mcg/g · Oint
· 1 products ·
Limited Use, codes 191 · strengths: 3mcg/g · Oint
· 2 products ·
Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr
· 1 products ·
Limited Use, codes 383 · strengths: 1% · Cr
· 3 products ·
Limited Use, codes 574 · strengths: 75mg/0.83mL, 150mg/mL · Inj Sol-0.83mL Pref Syr (Preservative-Free), Inj Sol-Pref Pen (Preservative-Free), Inj Sol-Pref Syr (Preservative-Free)
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:36
and 3 more